Alghamri Mahmoud S, Kamran Neha, Kadiyala Padma, Lowenstein Pedro Ricardo, Castro Maria Graciela
Department of Neurosurgery, University of Michigan Medical School, MSRB II, Ann Arbor, MI, United States; Department of Cell and Developmental Biology, University of Michigan Medical School, MSRB II, Ann Arbor, MI, United States.
Department of Neurosurgery, University of Michigan Medical School, MSRB II, Ann Arbor, MI, United States; Department of Cell and Developmental Biology, University of Michigan Medical School, MSRB II, Ann Arbor, MI, United States.
Methods Enzymol. 2020;632:215-228. doi: 10.1016/bs.mie.2019.05.047. Epub 2019 Jun 18.
Despite advances in uncovering the molecular mechanisms that mediate glioma progression and the implementation of novel therapeutic modalities, patients' prognosis remains dismal. This is due to both systemic and local tumor induced immune suppression. We are particularly interested in the role played by infiltrating immunosuppressive myeloid derived suppressor cells (MDSCs) in the glioma tumor microenvironment (TME). This immunosuppressive TME also interferes with the effectiveness of immunotherapies against glioma. Development of multipronged treatment approaches is imperative when aiming to generate a robust anti-glioma immune response. Evaluating the inhibitory potential of MDSCs within the TME is an important aspect for developing effective treatments for glioma. Herein, we discuss methodology to assess the inhibitory effects of MDSCs isolated from the TME using a mouse glioma model.
尽管在揭示介导胶质瘤进展的分子机制以及实施新型治疗方法方面取得了进展，但患者的预后仍然不佳。这是由于全身和局部肿瘤诱导的免疫抑制。我们特别关注浸润性免疫抑制性髓源性抑制细胞（MDSCs）在胶质瘤肿瘤微环境（TME）中所起的作用。这种免疫抑制性TME也会干扰针对胶质瘤的免疫疗法的有效性。当旨在产生强大的抗胶质瘤免疫反应时，开发多管齐下的治疗方法势在必行。评估TME内MDSCs的抑制潜力是开发有效胶质瘤治疗方法的一个重要方面。在此，我们讨论使用小鼠胶质瘤模型评估从TME中分离的MDSCs抑制作用的方法。
